HLA-DR and DQ antigen frequencies observed in SLE patients and controls from Singapore

<table>
<thead>
<tr>
<th>Antigen</th>
<th>SLE (n = 26)</th>
<th>Controls (n = 77)</th>
<th>n %</th>
<th>n %</th>
</tr>
</thead>
<tbody>
<tr>
<td>DR1</td>
<td>7</td>
<td>26-9</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>DR2</td>
<td>3</td>
<td>26-9</td>
<td>21</td>
<td>27.3</td>
</tr>
<tr>
<td>DR4</td>
<td>0</td>
<td>26-9</td>
<td>12</td>
<td>15.6</td>
</tr>
<tr>
<td>DR5</td>
<td>7</td>
<td>26-9</td>
<td>17</td>
<td>22.1</td>
</tr>
<tr>
<td>DR7</td>
<td>0</td>
<td>26-9</td>
<td>0</td>
<td>0.0</td>
</tr>
<tr>
<td>DR8</td>
<td>10</td>
<td>26-9</td>
<td>9.1</td>
<td></td>
</tr>
<tr>
<td>DR9</td>
<td>2</td>
<td>26-9</td>
<td>13</td>
<td>16.9</td>
</tr>
<tr>
<td>DQ1</td>
<td>0</td>
<td>26-9</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>DQ2</td>
<td>6</td>
<td>26-9</td>
<td>13</td>
<td>16.9</td>
</tr>
<tr>
<td>DQ4</td>
<td>4</td>
<td>26-9</td>
<td>15</td>
<td>19.5</td>
</tr>
<tr>
<td>DQ5</td>
<td>7</td>
<td>26-9</td>
<td>18</td>
<td>23.4</td>
</tr>
<tr>
<td>DQ6</td>
<td>15</td>
<td>26-9</td>
<td>37</td>
<td>48.2</td>
</tr>
<tr>
<td>DQ*0601</td>
<td>7</td>
<td>26-9</td>
<td>38</td>
<td>23.9</td>
</tr>
<tr>
<td>DQ*0602</td>
<td>3</td>
<td>26-9</td>
<td>10</td>
<td>9.1</td>
</tr>
<tr>
<td>DQ*0603-8</td>
<td>2</td>
<td>26-9</td>
<td>7</td>
<td>9.1</td>
</tr>
<tr>
<td>DQ8</td>
<td>5</td>
<td>26-9</td>
<td>19</td>
<td>24.7</td>
</tr>
<tr>
<td>DQ9</td>
<td>8</td>
<td>26-9</td>
<td>30</td>
<td>38.3</td>
</tr>
</tbody>
</table>

*χ² = 0.99; odds ratio 2-0; 95% confidence interval 0.51 to 7.83; p = 0.09.

also a non-significant increase in DR8.1 However, our most striking finding was the absence of a DR2 association with SLE, as this had been found in the studies from Hong Kong and Korea1 and in a further study from Kuala Lumpur, Malaysia.3

One possible explanation for these differences could be genetic admixture in the Singapore Chinese population, as there has been some intermingling with Malays, Indians, and Europeans since the seventeenth century. In contrast, Hong Kong Chinese were Chinese up in the previous century. This could explain the presence in the Singapore SLE patients of the typical white population SLE susceptibility haplotype carrying DR3 and DQ2. Another explanation could be ethnic heterogeneity among the southern Chinese, with approximately 75% of the Chinese migrated from Fujian Province, whereas 90% or more of the Hong Kong Chinese came from Guangdong Province. Unfortunately, the HLA distributions in these populations are not well characterised, but there may be significant differences which could have implications for the relative frequencies of MHC haplotypes (particularly DR2) predisposing to SLE in these populations.

MARTIN RUDWALEIT
KATHRYN GIBSON
PAUL WORDSWORTH
Nuffield Department of Clinical Medicine, John Radcliffe Hospital, Oxford, United Kingdom
KEVIN PILE
Queen Elizabeth Hospital, Woodville, Adelaide 5011, Australia
VERNON OH
National University Hospital, Singapore 119230

Correspondence to: Dr P Wordsworth, Nuffield Department of Clinical Medicine, John Radcliffe Hospital, Oxford OX3 9DU, United Kingdom

M Rudwaleit is supported by the Deutsche Akademischen Auschuss (DAAD). The authors are grateful for the financial support of the Arthritis and Rheumatism Council.


Treatment of refractory reflex sympathetic dystrophy with pamidronate

Reflex sympathetic dystrophy (RSD) is a condition affecting part of the arm, and is characterised by pain, vasomotor disturbance and trophic changes. RSD can persist for months or years and be severely disabling.2 Maladaptive pain is characterised by local osteoporosis, which corresponds to osteoclast hyperactivity. Calcitonin, an anti-osteoclastic drug, has been shown to help some patients.2 Pamidronate, a second generation bisphosphonate, is a potent anti-osteoclastic agent,3 which is the rationale for using it in the treatment of RSD.

In an open prospective study, we evaluated the efficacy of pamidronate in the treatment of refractory RSD. Eleven patients (three men and eight women; mean age 51-3 (SD 12-8) years) suffering from RSD of at least six months duration (mean of 14-6 (10-3) months) refractory to calcitonin and physical therapy, were included. All patients fulfilled Douri’s criteria for the diagnosis of RSD.4 The involved sites were the foot (n = 5), the hand (n = 2), the upper limb (n = 2), the knee (n = 1), the lower limb (n = 1). In eight cases, the RSD was related to local injury. Six patients had had to stop work because of RSD.

Radiographs of the affected sites showed osteoporosis in all cases. The patients were given 30 mg of intravenous pamidronate in 500 ml of saline over four hours, daily, for three consecutive days. The patients received no standard treatment for their RSD from one month before the administration of pamidronate until three months after it. Patients were assessed by the same observer at baseline and after one and three months. Evaluation was on a Visual analogue scale for pain (VAS), and a physician global assessment (no improvement, moderate, significant or excellent improvement) based on objective signs on clinical evaluation (hyperesthesia, temperature changes, joint stiffness). Blood cell count and serum calcium (corrected with serum albuminemia) were measured before, during, and one and three days after the administration of pamidronate.

The mean VAS decreased from 58-8/100 (20-2) before therapy, to 41-1/100 (26.8) at one month (p < 0.05; Wilcoxon paired test) and 33-8/100 (29) at three months (p < 0.01). In the physician global assessment, the results were: no improvement (n = 4), moderate improvement (n = 1), significant improvement (n = 3), and excellent improvement (n = 3) at one and three months. Three of the six patients who had had to stop work had returned to work after three months. We were unable to find predictive factors for efficacy (age, gender, affected site, degree of osteopenia). Pamidronate was well tolerated, apart from cosmetic minor adverse effects: two patients had a transient fever, two patients had brief asymptomatic hypocalcaemia (2-05 mmol/l) and one patient had hypocalcaemia (2 mmol/l) associated with periaral paresthesia which resolved rapidly with oral calcium treatment (1 g/day).

It is not possible to say whether the observed improvements were attributable to the treatment, the natural history of the disease, or psychological factors, as pamidronate was not compared with placebo in a double blind trial. However, more than 50% of the patients suffering from chronic disease, previously refractory to treatment, showed significant or excellent improvement while taking pamidronate, suggesting that it was effective.

In conclusion, this study suggests that pamidronate is a safe and effective drug for the treatment of some refractory cases of RSD. Further double blind trials are required to confirm these results.

JEAN FRANCIS MAILLEFERT
CHRISTINE CHATARD
SUSANNAH OXEN
THIERRY PERRE
CHRISTIAN TAVERNIER
Department of Rheumatology, Hopital General, Dijon, France

JACQUES TEBIR
Department of Rheumatology, Centre Hospitalier Lyon-Sud, Pierre Bénite, France

Correspondence to: Dr J F Maillefert, Service de Rhumatologie, Hopital General, 3 rue du P Fraine, 21000 Dijon, France.


Pericardial tamponade preceding cutaneous involvement in systemic sclerosis

Cardiac involvement in systemic sclerosis may be primary, or secondary to involvement of other organ systems. Primary cardiac involvement in systemic sclerosis may be manifested as pericardial disease, myocardial disease, conduction system disease, or cardiac arrhythmias.1 Cardiac symptoms do not usually appear until late in the disease, but exceptionally may precede the recog-